Academic Journal
Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II – III elderly patients with colon cancer
| العنوان: | Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II – III elderly patients with colon cancer |
|---|---|
| المؤلفون: | Jueun Park, HyungJoo Baik, Sang Hyun Kang, Sang Hyuk Seo, Kwang Hee Kim, Min Kyung Oh, Hong Sub Lee, Sang Heon Lee, Ki Hyang Kim, Min Sung An |
| المصدر: | Asian Journal of Surgery, Vol 45, Iss 1, Pp 448-455 (2022) |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2022 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Geriatric patients, Colon cancer, Adjuvant chemotherapy, Surgery, RD1-811 |
| الوصف: | Summary: Purpose: 45% of colon cancer patients are elderly, yet they are often deviated from standard cancer management. The MOSAIC trial favored FOLFOX over FL with superior oncologic outcomes; however, which regimen is most beneficial in elderly population remains unclear. This study aimed to compare the efficacy of oxaliplatin-added chemotherapy and capecitabine monotherapy in high-risk stage II/stage III elderly colon cancer patients. Methods: Colon cancer patients ≥70 years of age who received adjuvant chemotherapy at Inje University Busan Paik Hospital between February 2009 to April 2016 were included. Patients were separated into the oxaliplatin-added group and capecitabine monotherapy group. The primary outcomes were CSS and OS. Results: Of 74 patients, 45 received oxaliplatin-added chemotherapy and 29 received capecitabine monotherapy. There was no difference between the two groups in CSS or OS (p = 0.9670 and p = 0.6801, respectively). The N stage was significantly associated with CSS in both uni/multivariate analysis (p = 0.0565 and p = 0.0347, respectively). The oxaliplatin-added group had more stage III patients, so we performed a subgroup analysis of CSS and OS based on stage, which also showed no significant difference. Conclusions: Capecitabine monotherapy is an oncologically safe regimen compared to oxaliplatin-added regimens in elderly patients with high-risk stage II/stage III colon cancer. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1015-9584 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S101595842100484X; https://doaj.org/toc/1015-9584; https://doaj.org/article/c4f7ebe53a874579a6675cbdde6cd036 |
| DOI: | 10.1016/j.asjsur.2021.07.067 |
| الاتاحة: | https://doi.org/10.1016/j.asjsur.2021.07.067 https://doaj.org/article/c4f7ebe53a874579a6675cbdde6cd036 |
| رقم الانضمام: | edsbas.4020E7AA |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 10159584 |
|---|---|
| DOI: | 10.1016/j.asjsur.2021.07.067 |